Description

Stenabolic (SR9009) ZPHC — 10 mg (100 tablets × 10 mg)

Product Overview

Stenabolic, known scientifically as SR9009, is a synthetic research compound developed as a potent agonist of the REV-ERB nuclear receptors (REV-ERBα and REV-ERBβ) . This pharmaceutical-grade product from ZPHC provides 100 film-coated tablets, each containing 10 mg of the active compound, offering precise dosing capabilities for research applications.

Mechanism of Action

SR9009 functions as a REV-ERB agonist, binding to these nuclear receptors with IC50 values of 670 nM for REV-ERBα and 800 nM for REV-ERBβ . The REV-ERB receptors play an integral role in regulating core clock proteins that drive circadian rhythms and metabolic processes . Activation of these receptors influences the expression of metabolic genes in the liver, skeletal muscle, and adipose tissue, resulting in increased energy expenditure .

Research has demonstrated that REV-ERB agonists like SR9009 can alter the circadian pattern of gene expression, affecting metabolic pathways involved in fatty acid oxidation, glucose metabolism, and lipid storage . Preclinical studies in animal models have shown that SR9009 administration leads to decreased fat mass and improvements in metabolic markers including dyslipidemia and hyperglycemia .

Key Features

Metabolic Support: As a REV-ERBα agonist, SR9009 boosts mitochondrial activity to promote higher calorie burning through enhanced fatty acid and glucose oxidation in skeletal muscle .

Endurance Enhancement: Research indicates that SR9009 can improve exercise capacity and training stamina by increasing metabolic activity in skeletal muscle without the use of stimulants .

Pure 10 mg Tablets: Each tablet is scored and film-coated, allowing for precise dose splitting to 5 mg for beginner research protocols.

Research-Grade Quality Control: ZPHC batches undergo laboratory testing to verify greater than 99% purity, with heavy-metal and microbiological clearance .

Cycle Guide: Typical research protocols suggest 10-30 mg daily administration over 6-8 weeks, often stacked with Cardarine or Ostarine for combined research applications .

Product Authenticity: Sealed blisters in tamper-evident packaging with scratch-code authenticity verification ensure product integrity.

Worldwide Shipping: Tracked shipping available to international destinations.

Product Specifications

• Active Ingredient: Stenabolic (SR9009)

• Strength: 10 mg per tablet

• Quantity: 100 tablets

• Form: Scored, film-coated tablets

• Purity: Greater than 99% (lab-tested)

• Manufacturer: ZPHC

• Packaging: Sealed blisters in tamper-evident box with authenticity scratch-code

Research Applications

SR9009 is a research compound with potential applications in the study of:

• Circadian rhythm regulation and sleep disorders 

• Metabolic disease including obesity and dyslipidemia 

• Exercise capacity and endurance enhancement 

• Mitochondrial function and energy metabolism 

• Inflammatory response and immune function 

Top 10 Frequently Asked Questions

1. Is SR9009 a SARM?
No, SR9009 (Stenabolic) is not a Selective Androgen Receptor Modulator (SARM). It is a REV-ERB agonist that functions through a completely different mechanism, targeting nuclear receptors involved in circadian rhythm and metabolism regulation .

2. What is the typical research dosage for SR9009?
Standard research protocols typically employ 20-30 mg per day, often divided into multiple administrations due to the compound’s short half-life. Some researchers begin with 5 mg twice daily (10 mg total) and titrate upward based on research objectives .

3. What is the half-life of SR9009?
SR9009 has a relatively short half-life, typically requiring administration 2-4 times per day to maintain consistent research effects. This is one of the primary considerations when designing research protocols .

4. How does SR9009 work?
SR9009 acts as an agonist for REV-ERBα and REV-ERBβ nuclear receptors, which are integral components of the molecular clock system. Activation of these receptors alters the expression of metabolic genes in the liver, skeletal muscle, and adipose tissue, leading to increased energy expenditure and mitochondrial activity .

5. What are the reported benefits of SR9009 in research?
Research has demonstrated potential benefits including increased energy expenditure, reduced fat mass, improved glucose metabolism, enhanced exercise endurance, and alterations in circadian rhythm patterns .

6. Is SR9009 approved for human use?
No, SR9009 is not approved by the U.S. Food and Drug Administration for human medical use and is strictly classified as a research chemical for investigational purposes only .

7. What is the typical cycle length for SR9009 research?
Research protocols typically run for 6-8 weeks, after which a discontinuation period is recommended to assess outcomes. Some researchers incorporate SR9009 into longer-term study designs .

8. Can SR9009 be stacked with other research compounds?
Yes, SR9009 is frequently researched in combination with Cardarine (GW-501516) for enhanced endurance effects, or with Ostarine (MK-2866) for combined metabolic and anabolic research applications .

9. Does SR9009 have any known side effects?
As a research compound, comprehensive safety data in humans is limited. Preclinical studies indicate potential effects on circadian rhythm regulation and metabolic pathways. The compound has been associated with REV-ERB-independent effects on cell proliferation in certain models .

10. What is the bioavailability of oral SR9009?
Oral bioavailability of SR9009 has been reported to be relatively low in some research, which has led to consideration of alternative administration routes in research settings and the development of compounds like SR9011 with improved properties .

Purchase Information

Price: $125.00

Secure your research supply of this pharmaceutical-grade Stenabolic (SR9009) from ZPHC today. Each order includes sealed blisters in tamper-evident packaging with authenticity verification.

Visit: https://anabolicsteroidsonline.shop/

References

1. InvivoChem. “SR9009 | REV-ERBα/β agonist | CAS 1379686-30-2.” 

2. National Institutes of Health (NIH). “GSM3500552: Hepatocytes_Control_S9009_Rep1.” 

3. ProbeChem. “SR9009 Product Data Sheet.” 

4. AbMole BioScience. “Stenabolic (SR9009) Product Information.” 

5. Trustpilot. “ZPHC Reviews.” 

6. Bossgoo. “SR9009 Product Description.” 

7. Grokipedia. “SR9009 Research Compound Information.”